BrightSpring Health Services, Inc. (BTSG) Stock Price & Analysis
BrightSpring Health Services, Inc. (BTSG) closed at USD 60.86 on Thursday, October 22, 2026, down 2.41% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 62.36; the Oct 22, 2026 session ranged USD 59.79–62.04 on volume of 2,146,498 shares. Market capitalization is $12.04B, with a 52-week range of USD 30.64–73.75 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BTSG.md
Key facts (BTSG)
- Last four reported quarters (through Jun 30, 2026): revenue $14.4B, net income $366M (2.5% margin), free cash flow $402M (SEC filings).
- Valuation: P/E 32.9x (avg 43.2x at the last 1 fiscal year-ends), EV/EBITDA 22.5x, net debt $1.64B.
- 1 of 80 tracked superinvestors hold BTSG (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.83 on a 1–5 scale) (18 analysts), mean target USD 78.94 (range 70–90).
- Total return with dividends: 1Y +81.7% vs S&P 500 +14.9%; 5Y +453.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 0.47, revenue estimate $3.87B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BTSG)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $7.72B | $7.69B | $10.1B | $12.9B | $14.4B |
| Gross profit | $1.35B | $1.14B | $1.27B | $1.52B | — |
| Operating income | $188M | $58.1M | $108M | $295M | $448M |
| Net income | -$53.9M | -$155M | -$18.1M | $191M | $366M |
| EPS (diluted) | -$0.46 | -$1.31 | -$0.09 | $0.87 | — |
| Free cash flow | -$74.8M | $137M | -$57.1M | $395M | $402M |
| Gross margin | 17.5% | 14.8% | 12.6% | 11.8% | — |
| Operating margin | 2.4% | 0.8% | 1.1% | 2.3% | 3.1% |
| Net margin | -0.7% | -2.0% | -0.2% | 1.5% | 2.5% |
| Revenue growth | — | -0.4% | +31.0% | +28.2% | — |
| Cash + short-term investments | — | $13.1M | $61.0M | $88.4M | — |
| Total debt | — | $3.36B | $2.61B | $2.51B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BTSG)
P/E 32.9x · P/S 0.8x · EV/EBITDA 22.5x · EV/Sales 0.9x · P/FCF 29.9x · P/B 5.9x · FCF yield 3.34% · Earnings yield 3.04% · Net debt $1.64B · EV $13.7B
P/E at fiscal year-ends: Dec 2025 43.2x.
Superinvestors (SEC 13F-HR, Q2 2026) (BTSG)
1 of 80 tracked investors hold BTSG. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.32% | $113M | New position |
Analysts (BTSG)
Consensus Buy (mean 1.83 on a 1–5 scale), 18 analysts; mean target USD 78.94 (low 70, high 90).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | BTIG | Reiterated | Buy | $90 |
| 2026-08-03 | BTIG | Reiterated | Buy | $90 |
| 2026-07-14 | Morgan Stanley | Target raised | Overweight | $71 → $80 |
| 2026-07-14 | Keybanc | Target raised | Overweight | $60 → $80 |
| 2026-07-13 | Wells Fargo | Target raised | Overweight | $61 → $78 |
| 2026-07-13 | Guggenheim | Initiated | Buy | $81 |
| 2026-07-10 | Raymond James | Initiated | Outperform | $80 |
| 2026-07-08 | UBS | Target raised | Buy | $63 → $85 |
| 2026-07-02 | B of A Securities | Target raised | Buy | $66 → $77 |
Total return (dividends reinvested) (BTSG)
| 1Y (from 2025-10-23) | 5Y (from 2024-01-22) | |
|---|---|---|
| Total return | +81.7% | +453.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +82.0% | +86.3% |
| Volatility (annualized) | 44.2% | 43.1% |
| Max drawdown | -23.6% (Jul 2026→Sep 2026) | -29.7% (Jan 2025→Apr 2025) |
BTSG analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.47 | $0.44 | +7.8% | $3.87B | 16 |
| Next quarter (ends Dec 2026) | $0.51 | $0.47 | +8.7% | $4.01B | 16 |
| Current fiscal year (ends Dec 2026) | $1.82 | $1.69 | +7.7% | $15.37B | 17 |
| Next fiscal year (ends Dec 2027) | $2.28 | $2.12 | +7.2% | $17.43B | 17 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 60.86 |
|---|---|
| Change | ▼ 2.41% (down) |
| Previous Close | USD 62.36 |
| Open | USD 61.91 |
| Day Range | USD 59.79 – 62.04 |
| 52-Week Range | USD 30.64 – 73.75 |
| Volume | 2,146,498 shares |
| Market Cap | $12.04B |
| Exchange | NMS |
Technical Analysis (BTSG)
Nexqual's technical model rates BTSG "NEUTRAL" based on 3 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.93 (neutral) |
| vs SMA50 | Above (USD 59.87) |
| MACD | 0.67 (positive) |
Analyst Ratings (BTSG)
Wall Street analysts rate BTSG "Buy" based on 18 analysts, with a mean price target of USD 78.94 (range USD 70–90), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 78.94 |
| High Target | USD 90 |
| Low Target | USD 70 |
| Buy / Hold / Sell | 18 / 0 / 0 |
Earnings (BTSG)
| Next Earnings Date | 2026-10-30 |
|---|---|
| EPS Estimate | USD 0.47 |
| Revenue Estimate | $3.87B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.45 vs est 0.4 ▲ beat |
| 2026-03-31 | USD 0.39 vs est 0.31 ▲ beat |
| 2025-12-31 | USD 0.33 vs est 0.35 ▼ miss |
| 2025-09-30 | USD 0.3 vs est 0.26 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (BTSG)
| Total Revenue | $14.37B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +23.00% |
| Gross Margin | +12.38% |
| Operating Margin | +3.37% |
| Profit Margin | +2.55% |
| ROE | +13.04% |
| Debt / Equity | 1.16 |
| Current Ratio | 1.59 |
| Total Cash | $550.38M |
| Total Debt | $2.39B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $402.35M (2.8% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (BTSG)
Nexqual rates BrightSpring Health Services, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Solid — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 12%, operating 3% (last 12 months) |
| Balance Sheet | Mixed — $550M cash and investments vs $2.19B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $402M (last 4 quarters to Jun 2026, SEC), slim 2.8% margin |
| Efficiency | Mixed — ROE 13%, ROA 4.9% |
Ownership (BTSG)
| Insider Ownership | +3.12% |
|---|---|
| Institutional Ownership | +108.24% |
| Shares Outstanding | 197.86M |
| Float | 150.65M |
| Short % of Float | +9.39% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (BTSG)
BrightSpring Health Services, Inc. is led by Jon B. Rousseau, Chairman, President & CEO, per Nexqual as of October 23, 2026 at 09:26 UTC.
| Chairman, President & CEO | Jon B. Rousseau |
|---|---|
| CFO, Executive VP & Corporate Secretary | Jennifer A. Phipps |
| Executive VP & President of PharMerica | Scott Greenwell Pharm.D. |
| Senior VP of Strategic Finance & IR and Executive Director of BrightSpring Health Foundation | David J. Deuchler C.F.A. |
| Senior Vice President of Government Relations | Daryn Demeritt |
Major Backers & Investors (BTSG)
Notable institutional backers of BrightSpring Health Services, Inc. include Kohlberg Kravis Roberts & Co. L.P., FMR, LLC, Invesco, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 13.56% |
| FMR, LLC | 6.77% |
| Invesco | 6.04% |
| Price (T.Rowe) Associates Inc | 5% |
| T. Rowe Price | 3.05% |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 1.56% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.14% |
| Vanguard Group | 8.73% |
| State Street | 3.17% |
| Geode Capital | 2.62% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TEM | Tempus AI, Inc. | USD 63.81 | ▼ 5.83% |
| HNGE | Hinge Health, Inc. | USD 109.93 | ▼ 1.85% |
| HQY | HealthEquity, Inc. | USD 100.97 | ▲ 3.16% |
| DOCS | Doximity, Inc. | USD 33.68 | ▲ 0.3% |
| WAY | Waystar Holding Corp. | USD 28.98 | ▲ 0.49% |
| HTFL | Heartflow, Inc. | USD 55.43 | ▼ 0.7% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt